FY2027 EPS Estimates for MiMedx Group Lowered by Analyst

MiMedx Group, Inc (NASDAQ:MDXG) – Analysts at Northland Securities reduced their FY2027 EPS estimates for shares of MiMedx Group in a research report issued to clients and investors on Tuesday, January 20th. Northland Securities analyst C. Byrnes now forecasts that the company will post earnings of $0.20 per share for the year, down from their previous forecast of $0.45. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.08. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. The firm had revenue of $113.73 million during the quarter, compared to the consensus estimate of $94.74 million.

A number of other equities research analysts have also recently commented on MDXG. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Mizuho reduced their price objective on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Lake Street Capital dropped their price objective on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, MiMedx Group presently has an average rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Stock Down 2.7%

MDXG stock opened at $5.27 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95. The company’s 50 day simple moving average is $6.58 and its 200-day simple moving average is $6.87. MiMedx Group has a 12 month low of $5.13 and a 12 month high of $9.30. The firm has a market capitalization of $780.93 million, a PE ratio of 19.53 and a beta of 1.57.

Institutional Trading of MiMedx Group

A number of institutional investors have recently modified their holdings of the company. Phocas Financial Corp. raised its holdings in MiMedx Group by 17.1% in the fourth quarter. Phocas Financial Corp. now owns 492,991 shares of the company’s stock valued at $3,338,000 after buying an additional 72,037 shares during the period. Allspring Global Investments Holdings LLC grew its stake in MiMedx Group by 433.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock worth $1,958,000 after buying an additional 234,958 shares during the period. SG Americas Securities LLC increased its position in shares of MiMedx Group by 16.1% in the fourth quarter. SG Americas Securities LLC now owns 188,045 shares of the company’s stock worth $1,273,000 after acquiring an additional 26,085 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in shares of MiMedx Group in the 3rd quarter valued at $487,000. Finally, CIBC Bancorp USA Inc. acquired a new position in shares of MiMedx Group during the 3rd quarter valued at $88,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Insider Activity at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $7.42, for a total transaction of $432,586.00. Following the transaction, the insider directly owned 236,982 shares in the company, valued at $1,758,406.44. This represents a 19.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.70% of the stock is currently owned by corporate insiders.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.